Development of a gene therapy strategy to target hepatocellular carcinoma based inhibition of protein phosphatase 2A using the α-fetoprotein promoter enhancer and pgk promoter: An in vitro and in vivo study

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Li, Wei ^a,b   Li, Dao Ming ^a   Chen, Kai ^a   Chen, Zheng ^b   Zong, Yang ^b   Yin, Hong ^a   Xu, Ze Kuan ^b   Zhu, Yi ^b   Gong, Fei Ran ^a   Tao, Min ^a,c  

^a THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^c SOOCHOW UNIVERSITY   (China)

Author keywords

AFP; Hepatocellular carcinoma; Pgk; PP2A

Indexed keywords

ADENOVIRUS VECTOR; ALPHA FETOPROTEIN; PHOSPHOGLYCERATE KINASE; PHOSPHOPROTEIN PHOSPHATASE 2A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER GENE THERAPY; CANCER INHIBITION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG TARGETING; ENHANCER REGION; ENZYME ACTIVE SITE; ENZYME INHIBITION; ENZYME SPECIFICITY; G2 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; HOUSEKEEPING GENE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; PGK GENE; PROMOTER REGION; TUMOR XENOGRAFT; VIRAL GENE DELIVERY SYSTEM;

ALPHA-FETOPROTEINS; ANIMALS; APOPTOSIS; CANTHARIDIN; CARCINOMA, HEPATOCELLULAR; CELL CYCLE; CELL LINE, TUMOR; ENHANCER ELEMENTS, GENETIC; ENZYME INHIBITORS; GENETIC THERAPY; HUMANS; LIVER NEOPLASMS, EXPERIMENTAL; MICE; MICE, NUDE; NEOPLASM PROTEINS; PHOSPHOGLYCERATE KINASE; PROMOTER REGIONS, GENETIC; PROTEIN PHOSPHATASE 2;

EID: 84869881879     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-547     Document Type: Article

References (27)

1. Orito E, Mizokami M. Differences of HBV genotypes and hepatocellular carcinoma in Asian countries. Hepatol Res 2007, 37(s1):S33-35. 10.1111/j.1872-034X.2007.00101.x, 17627633.
2. Hainaut P, Boyle P. Curbing the liver cancer epidemic in Africa. Lancet 2008, 371(9610):367-368. 10.1016/S0140-6736(08)60181-6, 18242399.
3. Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 2006, 6(9):674-687. 10.1038/nrc1934, 16929323.
4. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55(2):74-108. 10.3322/canjclin.55.2.74, 15761078.
5. Xu Z, Fan X, Xu Y, Di Bisceglie AM. Comparative analysis of nearly full-length hepatitis C virus quasispecies from patients experiencing viral breakthrough during antiviral therapy: clustered mutations in three functional genes, E2, NS2, and NS5a. J Virol 2008, 82(19):9417-9424. 10.1128/JVI.00896-08, 2546966, 18667493.
6. Wang GS. Medical uses of mylabris in ancient China and recent studies. J Ethnopharmacol 1989, 26(2):147-162. 10.1016/0378-8741(89)90062-7, 2689797.
7. Li W, Xie L, Chen Z, Zhu Y, Sun Y, Miao Y, Xu Z, Han X. Cantharidin, a potent and selective PP2A inhibitor, induces an oxidative stress-independent growth inhibition of pancreatic cancer cells through G2/M cell-cycle arrest and apoptosis. Cancer Sci 2010, 101(5):1226-1233. 10.1111/j.1349-7006.2010.01523.x, 20331621.
8. Millward TA, Zolnierowicz S, Hemmings BA. Regulation of protein kinase cascades by protein phosphatase 2A. Trends Biochem Sci 1999, 24(5):186-191. 10.1016/S0968-0004(99)01375-4, 10322434.
9. Janssens V, Goris J, Van Hoof C. PP2A: the expected tumor suppressor. Curr Opin Genet Dev 2005, 15(1):34-41. 10.1016/j.gde.2004.12.004, 15661531.
10. Li W, Chen Z, Zong Y, Gong F, Zhu Y, Lv J, Zhang J, Xie L, Sun Y, Miao Y, et al. PP2A inhibitors induce apoptosis in pancreatic cancer cell line PANC-1 through persistent phosphorylation of IKKalpha and sustained activation of the NF-kappaB pathway. Cancer letters 2011, 304(2):117-127. 10.1016/j.canlet.2011.02.009, 21376459.
11. Li W, Chen Z, Gong FR, Zong Y, Chen K, Li DM, Yin H, Duan WM, Miao Y, Tao M, et al. Growth of the pancreatic cancer cell line PANC-1 is inhibited by protein phosphatase 2A inhibitors through overactivation of the c-Jun N-terminal kinase pathway. Eur J Cancer 2011, Epub ahead of print.
12. Cao G, Kuriyama S, Gao J, Nakatani T, Chen Q, Yoshiji H, Zhao L, Kojima H, Dong Y, Fukui H, et al. Gene therapy for hepatocellular carcinoma based on tumour-selective suicide gene expression using the alpha-fetoprotein (AFP) enhancer and a housekeeping gene promoter. Eur J Cancer 2001, 37(1):140-147. 10.1016/S0959-8049(00)00344-0, 11165141.
13. Evans DR, Myles T, Hofsteenge J, Hemmings BA. Functional expression of human PP2Ac in yeast permits the identification of novel C-terminal and dominant-negative mutant forms. J Biol Chem 1999, 274(34):24038-24046. 10.1074/jbc.274.34.24038, 10446173.
14. Carmichael J, DeGraff WG, Gazdar AF, Minna JD, Mitchell JB. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer research 1987, 47(4):936-942.
15. Ma T, Zhu ZG, Ji YB, Zhang Y, Yu YY, Liu BY, Yin HR, Lin YZ. Correlation of thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase with sensitivity of gastrointestinal cancer cells to 5-fluorouracil and 5-fluoro-2'-deoxyuridine. World J Gastroenterol 2004, 10(2):172-176.
16. Weiner MP, Costa GL, Schoettlin W, Cline J, Mathur E, Bauer JC. Site-directed mutagenesis of double-stranded DNA by the polymerase chain reaction. Gene 1994, 151(1-2):119-123.
17. Nelson M, McClelland M. Use of DNA methyltransferase/endonuclease enzyme combinations for megabase mapping of chromosomes. Methods Enzymol 1992, 216:279-303.
18. Kita-Matsuo H, Barcova M, Prigozhina N, Salomonis N, Wei K, Jacot JG, Nelson B, Spiering S, Haverslag R, Kim C, et al. Lentiviral vectors and protocols for creation of stable hESC lines for fluorescent tracking and drug resistance selection of cardiomyocytes. PloS one 2009, 4(4):e5046. 10.1371/journal.pone.0005046, 2662416, 19352491.
19. Nakabayashi H, Hashimoto T, Miyao Y, Tjong KK, Chan J, Tamaoki T. A position-dependent silencer plays a major role in repressing alpha-fetoprotein expression in human hepatoma. Mol Cell Biol 1991, 11(12):5885-5893. 361738, 1719374.
20. He TC, Zhou S, da Costa LT, Yu J, Kinzler KW, Vogelstein B. A simplified system for generating recombinant adenoviruses. Proceedings of the National Academy of Sciences of the United States of America 1998, 95(5):2509-2514. 10.1073/pnas.95.5.2509, 19394, 9482916.
21. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 1991, 139(2):271-279. 10.1016/0022-1759(91)90198-O, 1710634.
22. Yeh CB, Su CJ, Hwang JM, Chou MC. Therapeutic effects of cantharidin analogues without bridging ether oxygen on human hepatocellular carcinoma cells. Eur J Med Chem 2010, 45(9):3981-3985. 10.1016/j.ejmech.2010.05.053, 20691337.
23. Zheng LH, Bao YL, Wu Y, Yu CL, Meng X, Li YX. Cantharidin reverses multidrug resistance of human hepatoma HepG2/ADM cells via down-regulation of P-glycoprotein expression. Cancer letters 2008, 272(1):102-109. 10.1016/j.canlet.2008.06.029, 18703276.
24. Honkanen RE. Cantharidin, another natural toxin that inhibits the activity of serine/threonine protein phosphatases types 1 and 2A. FEBS Lett 1993, 330(3):283-286. 10.1016/0014-5793(93)80889-3, 8397101.
25. Zabner J, Wadsworth SC, Smith AE, Welsh MJ. Adenovirus-mediated generation of cAMP-stimulated Cl- transport in cystic fibrosis airway epithelia in vitro: effect of promoter and administration method. Gene Ther 1996, 3(5):458-465.
26. Fallaux FJ, Bout A, van der Velde I, van den Wollenberg DJ, Hehir KM, Keegan J, Auger C, Cramer SJ, van Ormondt H, van der Eb AJ, et al. New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses. Hum Gene Ther 1998, 9(13):1909-1917. 10.1089/hum.1998.9.13-1909, 9741429.
27. Regulier E, Schneider BL, Deglon N, Beuzard Y, Aebischer P. Continuous delivery of human and mouse erythropoietin in mice by genetically engineered polymer encapsulated myoblasts. Gene Ther 1998, 5(8):1014-1022. 10.1038/sj.gt.3300687, 10326023.